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RESULTS: Healthcare utilization and concomitant costs
(denominated in the Euro) for naive type 2 diabetic patients
initiated on Diamicron varied greatly between these prac-
tices in the UK and France. The biggest difference in utiliza-
tion was greater use in France of hospital inpatient and hos-
pital outpatient services. Total annual direct medical costs
in France were approximately 1,620 Euro (10,600FF), com-
pared with 454 Euro (320 BP) in the UK. Costs of Diami-
cron, as actually prescribed and used by the patients, also
varied considerably: 112 Euro in France versus 65 Euro in
the UK.
CONCLUSION: Patient care and associated costs for pa-
tients newly diagnosed with a common clinical condition
such as diabetes can vary considerably even within popu-
lous western European nations. Analyses of cost of illness
and cost effectiveness must be careful to use country-spe-
cific data in order to maximize the utility of these analyses
by relevant decision-makers within those countries.
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OBJECTIVE: To offer direct cost estimates of patients with
diabetes mellitus based on retrospectively collected data.
METHODS: A multicenter, retrospective observational
study on 30 diabetic centres located in 12 different re-
gions of Italy. Each diabetes centre randomly selected be-
tween 60 and 100 patients with diabetes mellitus. A total
of 2,135 patients were enrolled. For each patient data on
resource consumption was collected retrospectively—on
the two months preceding the enrolment—using a ques-
tionnaire filled in by physicians of the participant centres.
Per patient-year direct cost estimates were produced, tak-
ing the Italian National Health Service (INHS) perspec-
tive, by linking per patient service use data with INHS
tariffs of day-hospital admissions, outpatient visits, labo-
ratory and diagnostic tests, and drug prices. Drug cost
was calculated by multiplying the daily dose by the pub-
lic price when taken at home, and by 50% of the public
price when taken in hospital and ambulatory setting.
RESULTS: Total direct medical cost per patient was on av-
erage Italian L. 1,708,364 for Type I diabetes (N  572;
mean age 51.7) and L. 1,623,728 for Type II diabetes (N 
1,563; mean age 61.4). Drugs accounted for 32% of the
total cost in Type I patients and 17% in Type II, while out-
patient care, day-hospital admissions included, accounted
for 68% and 83%. Inpatient costs were not included.
CONCLUSION: This study suffers some major limits. Only
patients, and not centres, were randomly selected; resource
use data was retrospectively collected over two months of
observations, and unit costs were based on INHS tariffs.
However, since in Italy the cost of diabetes has received lim-
ited attention, we believe this study presents some interest-
ing information on the burden of diabetes in this country.
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OBJECTIVES: As part of a pan-European cost of illness
study in eight countries (CODE-2*: Costs of Diabetes in
Europe, Type 2) the CODE-2* UK objective was to mea-
sure cost of care for patients with type 2 diabetes (T2D) in
terms of management and complication costs in the UK.
METHODS: This was a bottom-up, prevalence-based
study design, which collected resource use and clinical out-
come data across primary and secondary care. Data
sources include comprehensive population-based diabetes
registers (the ‘primary databases’) and hospital and pri-
mary care records (‘secondary databases’). 756 T2D pa-
tients (defined as aged 30 or above at diagnosis) were iden-
tified from 3 registers. Clinical data was reviewed against
treatment guidelines to assess status of T2D management.
Preliminary results based on data in the 6-month period
July 1st to December 31st 1998 were analyzed first.
RESULTS: Assuming a UK prevalence of T2D of 2% the
total direct medical costs for people with T2D in the UK in
1998 were estimated to be £1.83 billion or 3.4% of health-
care expenditure. Average costs for patients with T2D were
£1550 per year. The costs attributed to oral anti-diabetic
drugs comprised 2.7% of overall direct costs. Costs for pa-
tients with T2D with microvascular and macrovascular
complications with indicators of Insulin Resistance Syn-
drome were higher than for patients without complica-
tions. The proportion of patients achieving good glycemic
control (6.5% HBA1c) decreased as patients progressed
from diet and exercise through to insulin alone or in com-
bination, highlighting the progressively increasing need for
treatment as duration of disease increases.
CONCLUSIONS: CODE-2* UK provides evidence of di-
rect costs and management of T2D in the NHS. It is a rich
data set to inform Health Boards, Health Authorities and
Primary Care Groups of how costs are composed and the
likely outcomes seen for T2D management. *Trademark
of SmithKline Beecham plc.
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ABSTRACT OBJECTIVE: To develop a pharmacody-
namic-pharmacoeconomic model to compare effectiveness
and costs of anti-inflammatory therapies used in asthma
treatment.
